Biogen Inc

NASDAQ:BIIB   3:59:59 PM EDT
239.29
+2.62 (+1.11%)
4:48:01 PM EDT: $239.25 -0.04 (-0.02%)
Products

FDA Says Prescribing Information For Aduhelm Includes Warning For Amyloid-Related Imaging Abnormalities

Published: 06/07/2021 15:44 GMT
Biogen Inc (BIIB) - FDA Says Prescribing Information for Aduhelm Includes a Warning for Amyloid-related Imaging Abnormalities (aria).
FDA Says Another Warning for Aduhelm is for a Risk of Hypersensitivity Reactions, Including Angioedema and Urticaria.
Further Company Coverage: Biibo ((reuters.
Briefs@thomsonreuters.
Com;)).